RT Journal Article
SR Electronic
T1 SARS-CoV-2 Spike S1-specific IgG kinetic profiles following mRNA- versus vector-based vaccination in the general Dutch population
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.25.21265467
DO 10.1101/2021.10.25.21265467
A1 van den Hoogen, Lotus L.
A1 Verheul, Marije K.
A1 Vos, Eric R.A.
A1 van Hagen, Cheyenne C.E.
A1 van Boven, Michiel
A1 Wong, Denise
A1 Wijmenga-Monsuur, Alienke J.
A1 Smit, Gaby
A1 Kuijer, Marjan
A1 van Rooijen, Debbie
A1 Bogaard-van Maurik, Marjan
A1 Zutt, Ilse
A1 van Vliet, Jeffrey
A1 van der Klis, Fiona R.M.
A1 de Melker, Hester E.
A1 van Binnendijk, Robert S.
A1 den Hartog, Gerco
YR 2021
UL http://medrxiv.org/content/early/2021/10/26/2021.10.25.21265467.abstract
AB mRNA- and vector-based vaccines are used at a large scale to prevent COVID-19. We compared Spike S1-specific (S1) IgG antibodies after vaccination with mRNA-based (Comirnaty, Spikevax) or vector-based (Janssen, Vaxzevria) vaccines, using samples from a Dutch nationwide cohort. mRNA vaccines induced faster inclines and higher S1 antibodies compared to vector-based vaccines in adults 18-64 years old (n=2,412). For all vaccines, one dose resulted in boosting of S1 antibodies in adults with a history of SARS-CoV-2 infection. For Comirnaty, two to four months following the second dose (n=196), S1 antibodies in adults aged 18-64 years old (436 BAU/mL, interquartile range: 328-891) were less variable and median concentrations higher compared to those in persons ≥80 years old (366, 177-743), but differences were not statistically significant (p>0.100). Nearly all participants seroconverted following COVID-19 vaccination, including the aging population. These data confirm results from controlled vaccine trials in a general population, including vulnerable groups.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the Dutch Ministry of Health, Welfare and SportsAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was ethically approved by the Medical Research Ethics Committees United MEC-U and registered under trial number NL8473.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors